Core Viewpoint - The company held an online earnings briefing on September 2, 2025, to discuss its business development and engage with investors [1] Business Development Disclosure - The company started selling scleral lenses in March, which accounted for 0.6% of lens orders in the first half of the year, primarily targeting adult users and is in the initial promotion phase [1] - The ordinary soft lenses from Multi-vision Medical did not have sales in the first half but are set to be launched in the second half of the year [1] - The company completed industrial changes for Shangyue Qicheng in mid-August and will officially consolidate its financials in September, with current operations reported as good [1] Business Expansion - The company is expanding its service terminal business by enhancing both the content and scale, including the introduction of functional vision correction products, dry eye and visual fatigue solutions, and visual function training [2] - The sales department is being optimized with additional technical support and sales personnel in various regions, and a second distribution center has been established for hard lens sales [2] Collaboration and Capacity Planning - The company has partnered with numerous optical professional universities for talent development and technical research, allowing students to gain practical experience [3] - New production capacity for BFS sterile instruments and clean rooms has been established, with BFS production lines already producing disposable rinsing solutions and eye wash solutions [3] Other Key Points - In the first half of the year, revenue from rigid contact lens products accounted for 57.77% of total revenue, down from 62.06% in the same period last year [4] - The company has different management approaches for subsidiaries based on direct operations and minority shareholder operations [4] - Revenue from medical institutions has declined due to the cessation of atropine sales at the headquarters hospital, with some medical institution business downturns requiring further monitoring [4]

Sales Performance - Scleral lens sales started in March 2025, accounting for 0.6% of lens orders in the first half of the year, primarily targeting adults [1] - Sales data for July and August will be disclosed in the regular report [2] - Medical institution revenue declined due to the cessation of atropine sales, which previously generated approximately 9 million in sales during the same period last year [3] Market Expansion Strategies - The company is expanding service terminal construction by diversifying product offerings beyond myopia prevention and hard lenses to include functional vision correction products and other optical services [2] - Focus on acquiring and investing in established optical service institutions with user resources to enhance service terminal scale [2] - Efforts to increase sales force and invest in optical terminals to boost business scale outside of East China, where sales revenue accounted for 57.77% of total revenue, down from 62.06% in the same period last year [3] Collaboration and Talent Development - Established partnerships with numerous universities for training optical service personnel and collaborative research projects [2] - Continuous enhancement of cooperation with educational institutions to strengthen talent reserves and technical research collaboration [2] Production Capacity and Market Demand - BFS production line is currently producing disposable rinsing solutions and eye wash liquids, with plans to fully produce disposable care products upon obtaining necessary approvals [2] - Development of eye health products suitable for disposable packaging is underway [2] Customer Accessibility - Customers can locate nearby OPUKANG optical stores through the "OPUKANG Optical Member" WeChat mini-program or by contacting local sales representatives for partner store information [3]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) plans to invest 10 million yuan in Jiangsu Jiansan Biotechnology Co., Ltd. (referred to as "Jiansan Biotechnology") to acquire a 1.75% stake in the company, which has successfully developed high-purity ergothioneine [1] Group 1 - Toxin Pharmaceutical will use its own funds for the investment of 10 million yuan [1] - After the investment, Toxin Pharmaceutical will directly hold 1.75% of Jiansan Biotechnology's equity [1] - Jiansan Biotechnology has achieved the production of high-purity ergothioneine, with main products including ergothioneine skincare products, oral capsules, and eye wash solutions [1]